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Introduction
Cryopyrin-associated periodic syndrome (CAPS) presents
as rare, autosomal dominant disease spectrum, due to
mutations in the NLRP3-gene which lead to excessive
interleukin-1 (IL-1) release.
In patients with low-penetrance NLRP3 variants, the
clinical presentation varies widely. So far, a correlation
with a specific phenotype could not be demonstrated.
Objectives
The aim of this study was to analyze the association of
the V198M, R488K, and Q703K substitutions with a
specific phenotype, laboratory markers, and the response
to IL-1 inhibitors anakinra, canakinumab and rilonacept.
Methods
This multi-center observational study included 45
patients (26 children and 19 adults) (study group).
At baseline examination, all patients displayed some
symptoms suggestive of CAPS. Genetic analysis detected
one of the following NLRP3 variants: Q703K (n = 19),
R488K (n = 6), and V198M (n = 20).
Clinical presentation was recorded and inflammation
markers were analyzed. Data from follow-up visits were
also evaluated to assess response to IL-1 inhibitors.
Results were compared to a (control) group of CAPS
patients (n = 28) in which disease-causing mutations
had been confirmed (A439V, E311K, T348M).
Results
At baseline examination, study patients reported signs of
systemic inflammation such as fever (76%), headache
(73%), musculoskeletal symptoms (84%) and fatigue
(78%). Other CAPS-specific features were rash (80%),
conjunctivitis (44%) and sensorineural hearing loss (29%).
Compared to the control group, a history of eye
impairment, hearing loss and renal involvement was sig-
nificantly less frequent in the study group. However
study group patients presented significantly more often
with gastrointestinal symptoms such as abdominal pain
(56% versus 25%, p = 0.01) and gastroesophageal reflux
(22% versus 0%, p = 0.01). Also, a wide spectrum of
concomitant diseases such as thyroid disorders (7) and
neurological and psychiatric diseases were reported
(epilepsy (3), Asperger syndrome (2)).
Inflammation markers were only slightly increased: ESR
was elevated in 26% (9/35) and C-reactive protein (CRP)
in 34% (14/41). Serum amyloid A (SAA) was raised in 36%
(8/22) of the patients. Nine out of ten patients (90%) had
elevated TNF-a-levels at baseline examination.
Data from follow-up visits during the first year of
treatment was available from 20 patients, treated with
IL1 - inhibitors. Clinical disease activity was reduced in
all cases; 10 patients (50%) achieved full remission and
10 patients showed partial response to the treatment
with mild disease activity and/ or persistently elevated
inflammation markers.
Conclusion
Heterozygous carriers of the NLRP3 variants V198M,
R488K, and Q703K display distinct clinical characteristics
compared to CAPS patients with confirmed disease causing
mutations, including a high incidence of gastrointestinal
symptoms, only slightly elevated inflammatory parameters,
and a potentially inferior response to IL-1 inhibition. Also
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